Strategic intelligence for the radiation healthcare
Bringing value to businesses and investors!
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiopharmaceutical, cyclotron, proton therapy and brachytherapy.
We offer the most comprehensive set of reports and directories, with over 4,600 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.
We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts.
We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeated satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. The team brings together more than 50 years of expertise in the field of radiation healthcare.
The team brings together years of expertise in the field of radiation healthcare.
Paul-Emmanuel GOETHALS, MBA
Phone: +32 491 080 968
Paul-Emmanuel Goethals founded CSIntell in 2012 followed by MEDraysintell in 2013. He has 34 years of experience in consulting, business development-intelligence and investor relations with a unique understanding of the medical and healthcare markets, especially in Radiotherapy, Radiopharmacy. Throughout these years he made numerous reports on complex markets as well as outstanding company profiles at the full satisfaction of his successive clients.
Paul-Emmanuel holds an MBA from the University of Dallas and is a member of SCIP (Strategic and Competitive Intelligence Professionals, Texas, USA).
Prior founding MEDraysintell and CSIntell, Paul-Emmanuel was Vice President Business Development & Capital Markets and Special Counsel to the CEO at Eckert & Ziegler Group, a European group listed in Frankfurt, active in cancer therapy, radiometry, nuclear-medical imaging (2009-2012); Director Corporate Business Development & Investor Relations at IBA, a Belgian company listed in Brussels, active in Proton Therapy, Radiopharmacy, Dosimetry and Industrial Sterilization (1998-2009); Project Manager at Strategic Analysis Inc., a US management consulting firm active in Chemical and Pharmaceutical Business Intelligence (1994 - 1998); Finance Director & Board member at Evening Group SA, a Belgian company active in business events (1992-1993) and Marketing Specialist & Product Management at Chemviron Carbon, the European branch of a US chemical group (1989-1992).
Dr. Richard ZIMMERMANN
Phone: +33 6 82 80 06 00
Dr. Richard Zimmermann founded Chrysalium Consulting in 2012 and MEDraysintell in 2013. He is a chemistry engineer, with a PhD degree in organic chemistry obtained in 1984 from the University of Strasbourg, France followed by a post-doctoral at Georgetown University, Washington, DC.
He has 15 years of experience in research laboratories of conventional pharmaceutical companies (Beecham, Solvay Pharmaceuticals) in France, Germany and the Netherlands. And over 25 years’ experience in the radiopharmaceutical industry as head of Research & Development and business development (CIS bio, Schering Pharma, IBA Molecular).
He is the owner of Chrysalium Consulting, Co-founder of Global Morpho Pharma, Founder and President of the Oncidium Foundation, Co-founder of rad4med.be and Telix Pharmaceuticals Ltd., and former President of Medisystem and ANMI.
Member of 6 Scientific Advisory Boards.
Serge Goossens has an extended experience in transport and logistic of medical isotopes in Europe and the US. Prior joining MEDraysintell as Advisor, he was the CEO, until September 2017, of Isotopes Services International, a company he founded in 1988 in Belgium. He also co-founded ISOVital in France; both companies are active in the international distribution of radioactive isotopes for the pharmaceutical market.
Serge was also the president of EITA (European Isotopes Transport Association) until March 2018, a non-profit association focusing on transport and handling of radioactive isotopes, which he co-founded in 1998.
He co-organized the Symposiums on Medical Isotopes (Belgium) and was an active member of AIPES (Association of Imaging Producers & Equipment Suppliers) transport working group until 2018.
Dr. Jean-Luc VANDERHEYDEN
Jean-Luc Vanderheyden is an experienced pharmacist and PhD Analytical chemist (Université Libre de Bruxelles and University of Cincinnati) who has worked in small and large biotechnology and pharmaceutical R&D environment (including Mallinckrodt Medical/GE Healthcare) for 35 years. He is an expert in scientific, commercial and research analyses related to advanced technologies involving all forms of imaging, isotope supply worldwide and radiation therapy.
He founded JLVMI Consulting LLC in the USA in 2012 to address the demands bridging the research/commercial gap in Chemistry, Manufacturing and Control as well as Pharmacology/Toxicology, consulting on the current and future trends in molecular medicine, biomarker and ligand development through early stage clinical trials and commercialization. It also specializes in research and laboratory management for total safety and compliance.
Jean-Luc was a Visiting Associate Professor at the University of Massachusetts Medical School (2001-2005). He served as a member of the USP PET Radiopharmaceuticals Advisory Panel focusing on the revision of chapter <823> (2009) and a board member of the Society for Non-Invasive Imaging in Drug Development (2006-2011). He also is a member of the Quantitative Imaging Biomarkers Alliance (QIBA) technical committee on PET, the American Chemical Society (ACS), the Society of Nuclear Medicine (SNMMI) and the European Association of Nuclear Medicine.